Literature DB >> 26550594

Comparison of Intravenous Morphine with Sublingual Buprenorphine in Management of Postoperative Pain after Closed Reduction Orthopedic Surgery.

Ghasem Soltani1, Mahmood Khorsand1, Alireza Sepehri Shamloo1, Lida Jarahi1, Nahid Zirak1.   

Abstract

BACKGROUND: Postoperative pain is a common side effect following surgery that can significantly reduce surgical quality and patient's satisfaction. Treatment options are morphine and buprenorphine. We aimed to compare the efficacy of a single dose of intravenous morphine with sublingual buprenorphine in postoperative pain control following closed reduction surgery.
METHODS: This triple blind clinical trial was conducted on 90 patients referred for closed reduction orthopedic surgery. They were older than 18 years and in classes I and II of the American Society of Anesthesiologists (ASA) with an operation time of 30-90 minutes. Patients were divided into two groups of buprenorphine (4.5µg/kg sublingually) and morphine (0.2mg/kg intravenously). Baseline characteristics, vital signs, pain score, level of sedation and pharmacological side effects were recorded in the recovery room (at 0 and 30 minutes), and in the ward (at 3, 6 and 12 hours). SPSS version 19 software was used for data analysis and the significance level was set at P<0.05.
RESULTS: Ninety patients were studied, 60 males and 30 females with a mean age of 37.7±16.2 years. There was no significant difference between the two groups in terms of baseline characteristics. Pain score in the morphine group was significantly higher than the buprenorphine group with an average score of 2.5 (P<0.001). Postoperative mean heart rate in the buprenorphine group was four beats lower than the morphine group (P<0.001). Also, in the buprenorphine 48.6% and in the morphine group 86.7% of cases were conscious in recovery (P=0.001) with a higher rate of pruritus in the latter group (P=0.001).
CONCLUSION: Sublingual buprenorphine administration before anesthesia induction in closed reduction surgery can lead to better postoperative pain control in comparison to intravenous morphine. Due to simple usage and longer postoperative sedation, sublingual buprenorphine is recommended as a suitable drug in closed reduction surgery.

Entities:  

Keywords:  Intravenous morphine; Orthopedic surgery; Patient satisfaction; Post-operative pain; Sublingual buprenorphine

Year:  2015        PMID: 26550594      PMCID: PMC4628636     

Source DB:  PubMed          Journal:  Arch Bone Jt Surg        ISSN: 2345-461X


  13 in total

Review 1.  Chronic pain as an outcome of surgery. A review of predictive factors.

Authors:  F M Perkins; H Kehlet
Journal:  Anesthesiology       Date:  2000-10       Impact factor: 7.892

Review 2.  Outcomes research in regional anesthesia and analgesia.

Authors:  C L Wu; L A Fleisher
Journal:  Anesth Analg       Date:  2000-11       Impact factor: 5.108

3.  Sublingual buprenorphine compared to morphine delivered by a patient-controlled analgesia system as postoperative analgesia after prostatectomy.

Authors:  L Gaitini; B Moskovitz; E Katz; A Vaisberg; S Vaida; O Nativ
Journal:  Urol Int       Date:  1996       Impact factor: 2.089

4.  Sex differences in morphine analgesia: an experimental study in healthy volunteers.

Authors:  E Sarton; E Olofsen; R Romberg; J den Hartigh; B Kest; D Nieuwenhuijs; A Burm; L Teppema; A Dahan
Journal:  Anesthesiology       Date:  2000-11       Impact factor: 7.892

5.  A comparison of preoperative morphine and buprenorphine for postoperative analgesia for arthrotomy in dogs.

Authors:  D C Brodbelt; P M Taylor; G W Stanway
Journal:  J Vet Pharmacol Ther       Date:  1997-08       Impact factor: 1.786

6.  Sublingual buprenorphine for premedication and postoperative pain relief in orthopaedic surgery.

Authors:  A Risbo; B Chraemmer Jørgensen; P Kolby; J Pedersen; J F Schmidt
Journal:  Acta Anaesthesiol Scand       Date:  1985-02       Impact factor: 2.105

7.  Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.

Authors:  Stanislav Oifa; Tatiana Sydoruk; Ian White; Margaret P Ekstein; Nissim Marouani; Shoshana Chazan; Yehuda Skornick; Avi A Weinbroum
Journal:  Clin Ther       Date:  2009-03       Impact factor: 3.393

8.  [Continuous intravenous infusion with patient-controlled anesthesia for postoperative analgesia in cesarean section: morphine versus buprenorphine].

Authors:  G Capogna; D Celleno; M Sebastiani; P Costantino; S Reggio
Journal:  Minerva Anestesiol       Date:  1989 Jan-Feb       Impact factor: 3.051

9.  Analgesics and ENT surgery. A clinical comparison of the intraoperative, recovery and postoperative effects of buprenorphine, diclofenac, fentanyl, morphine, nalbuphine, pethidine and placebo given intravenously with induction of anaesthesia.

Authors:  A A van den Berg; N M Honjol; N V Prabhu; S Datta; C J Rozario; R Muraleedaran; D Savva
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

10.  A comparison of morphine and buprenorphine for analgesia after abdominal surgery.

Authors:  J P Bradley
Journal:  Anaesth Intensive Care       Date:  1984-11       Impact factor: 1.669

View more
  3 in total

1.  Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.

Authors:  Gertrud Haeseler; Dirk Schaefers; Natalie Prison; Jörg Ahrens; Xiaofei Liu; Annika Karch
Journal:  BMC Anesthesiol       Date:  2017-07-11       Impact factor: 2.217

2.  Effectiveness of Sublingual Buprenorphine and Fentanyl Pump in Controlling Pain After Open Cholecystectomy.

Authors:  Vadood Norozi; Ahmad Ghazi; Firouz Amani; Parya Bakhshpoori
Journal:  Anesth Pain Med       Date:  2021-08-08

Review 3.  The Routes of Administration for Acute Postoperative Pain Medication.

Authors:  Filomena Puntillo; Mariateresa Giglio; Giustino Varrassi
Journal:  Pain Ther       Date:  2021-07-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.